Expected impact of Inflation Reduction Act Medicare Drug Price Negotiation Program on Medicare Part D beneficiary out-of-pocket costs
Download the executive summary
Download the addendum reflecting actual MFPs
Pharmaceutical Research and Manufacturers of America (PhRMA) recently commissioned Milliman to analyze the impact of the Medicare Drug Price Negotiation Program (MDPNP) on Medicare Part D beneficiary out-of-pocket (OOP) costs. The Inflation Reduction Act introduces several significant changes to Medicare Part D, including the MDPNP, and many others. These changes impact Medicare Part D beneficiaries, pharmaceutical manufacturers, plan sponsors, and the federal government in different ways. In this report, we discuss:
- Key findings from the study
- Data, methodology, and assumptions
- Caveats, limitations, and qualifications
This report was commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA).
About the Author(s)
Expected impact of Inflation Reduction Act Medicare Drug Price Negotiation Program on Medicare Part D beneficiary out-of-pocket costs
We analyze the impact of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program on Part D beneficiary out-of-pocket costs.